drugset / Trial / NCT06435442
PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
A Phase 1 Study to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and Naproxen in Healthy Volunteers
Timeline
- Start
- 2024-06-03
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epaminurad | Small molecule | 6 mg | — |
| Subject | Epaminurad | Small molecule | 9 mg | — |
| Subject | Naproxen | Small molecule | 500 mg | — |
Indications
No indication recorded.